PEGBIO CO-B (02565.HK): to place 26.81 million new H shares at HK$2.985 each, raising about HK$77.16 million net

NewTimeSpace News: On 3 November 2026, PegBio Co., Ltd. (02565.HK) disclosed that on 2 November (after trading hours) it entered into a placing agreement with the sole placing agent to place, on a best-efforts basis, an aggregate of 26,813,000 new H shares to no fewer than six placees at HK$2.985 per share, representing a discount of 19.00% to the closing price of HK$3.685 on the same day and about 19.26% to the average closing price of the preceding five consecutive trading days.

The placing shares will be issued under the general mandate without further shareholder approval, representing approximately 6.95% of the issued H shares and about 6.50% of the enlarged H shares. The estimated gross and net proceeds are approximately HK$80.04 million and HK$77.16 million respectively, of which about 60% will be used for R&D of the next-generation product pipeline (including PB-2309, APGP6 and PB-2312), 20% for repayment of loans and strengthening the capital structure, and 20% for general corporate purposes and working capital.

The sole overall coordinator, capital markets intermediary and placing agent is Macquarie Capital Limited. Completion is subject to conditions including listing approval from the Listing Committee of HKEX, so the placing may or may not proceed. The company is a biotech company focused on innovative therapies for chronic diseases, especially metabolic diseases.